61 related articles for article (PubMed ID: 7524277)
1. [Correlation between bone gammagraphy and biochemical parameters in bone turnover in patients with prostate cancer].
Alcover J; Fernández-Conde M; Filella X; de Osaba MJ; Carretero P
Actas Urol Esp; 1994 Jun; 18(6):623-7. PubMed ID: 7524277
[TBL] [Abstract][Full Text] [Related]
2. Correlation between bone metabolic markers and bone scan in prostatic cancer.
Maeda H; Koizumi M; Yoshimura K; Yamauchi T; Kawai T; Ogata E
J Urol; 1997 Feb; 157(2):539-43. PubMed ID: 8996351
[TBL] [Abstract][Full Text] [Related]
3. [Is it possible to do without bone gammagraphy in the staging of prostatic cancer?].
Ruiz de la Roja JC; Llorente Abarca C; Romero Cagigal I; Páez Borda A; Fernández González I; Martín Osés E; Berenguer Sánchez A
Actas Urol Esp; 1995 Feb; 19(2):123-7. PubMed ID: 7539572
[TBL] [Abstract][Full Text] [Related]
4. [Value of bone gammagraphy and pain in the follow-up of carcinoma of the prostate].
Ruiz Cerdá JL; Llopis Minguez B; Server Pastor G; Vidal Moreno JF; Boronat Tormo F; Jiménez Cruz JF
Arch Esp Urol; 1989; 42 Suppl 2():206-8. PubMed ID: 2639624
[TBL] [Abstract][Full Text] [Related]
5. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
6. [Can we do without bone gammagraphy in the staging of prostatic cancer?].
Morote J; Olona M; Villa J; Reig C; López MA; de Torres JA; Soler A
Actas Urol Esp; 1992 Jun; 16(6):487-9; discussion 489-90. PubMed ID: 1509919
[TBL] [Abstract][Full Text] [Related]
7. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer.
Noguchi M; Kikuchi H; Ishibashi M; Noda S
Br J Cancer; 2003 Jan; 88(2):195-201. PubMed ID: 12610502
[TBL] [Abstract][Full Text] [Related]
8. Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate.
Oommen R; Geethanjali FS; Gopalakrishnan G; Chacko N; John S; Kanagasabapathy AS; Roul RK
Br J Radiol; 1994 May; 67(797):469-71. PubMed ID: 7514940
[TBL] [Abstract][Full Text] [Related]
9. [When should bone scanning be carried out in prostatic cancer?].
Pertusa Peña C; Albisu Tristán A; Llarena Ibarguren R
Actas Urol Esp; 1994 May; 18 Suppl():387-96. PubMed ID: 8073924
[TBL] [Abstract][Full Text] [Related]
10. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy.
Terris MK; Klonecke AS; McDougall IR; Stamey TA
J Nucl Med; 1991 Sep; 32(9):1713-7. PubMed ID: 1715394
[TBL] [Abstract][Full Text] [Related]
11. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
12. Chest-Wall Metastasis of Prostate Cancer.
Matei V; Bhushan S
J Gen Intern Med; 2015 Dec; 30(12):1888. PubMed ID: 25759188
[No Abstract] [Full Text] [Related]
13. Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover.
Scher HI; Curley T; Geller N; Dershaw D; Chan E; Nisselbaum J; Alcock N; Hollander P; Yagoda A
Cancer Treat Rep; 1987 Oct; 71(10):887-93. PubMed ID: 3308078
[TBL] [Abstract][Full Text] [Related]
14. Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer?
Sissons GR; Clements R; Peeling WB; Penney MD
Br J Radiol; 1992 Oct; 65(778):861-4. PubMed ID: 1384917
[TBL] [Abstract][Full Text] [Related]
15. Total and nondialyzable hydroxyproline excretion in Stage D2 prostate cancer.
Hopkins SC; Palmieri GM; Niell HB; Moinuddin M; Soloway MS
Cancer; 1984 Jan; 53(1):117-21. PubMed ID: 6689994
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of bone gammagraphy versus tumor markers (PSA/PAP) in monitoring cancer of the prostate].
Morote J; de Torres JA
Actas Urol Esp; 1990; 14(4):268-70. PubMed ID: 1702258
[TBL] [Abstract][Full Text] [Related]
17. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation on serum osteocalcin in advanced prostate cancer patients].
Abe H; Nakagami YJ; Ito H; Ikeda K; Oka F; Niwa N
Hinyokika Kiyo; 1991 Aug; 37(8):877-80. PubMed ID: 1720275
[TBL] [Abstract][Full Text] [Related]
19. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up.
Freitas JE; Gilvydas R; Ferry JD; Gonzalez JA
J Nucl Med; 1991 Jul; 32(7):1387-90. PubMed ID: 1712383
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A
Prostate Cancer Prostatic Dis; 2009; 12(1):94-9. PubMed ID: 18332901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]